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Abstract Actinomycins, a family of bicyclic chromopeptide
lactones with strong antineoplastic activity, were screened as
inhibitors of Shc/Grb2 interaction in in vitro assay systems. To
investigate the effects of actinomycin D on Shc/Grb2 interaction
in cell-based experiments, we used SAA (normal hEGFR-
overexpressed NIH3T3) cells and B104-1-1 (neu*-transformed
NIH3T3) cells, because a large number of the Shc/Grb2
complexes were detected. Associated protein complexes contain-
ing Shc were immunoprecipitated from actinomycin D-treated
cell lysates with polyclonal anti-Shc antibody. Then the
association with Grb2 was assessed by immunoblotting with
monoclonal anti-Grb2 antibody. The result of the immunoblot-
ting experiment revealed that actinomycin D inhibited Shc/Grb2
interaction in a dose-dependent manner in both B104-1-1 and
EGF-stimulated SAA cells. The inhibition of Shc/Grb2 interac-
tion by actinomycin D in B104-1-1 cells also reduced tyrosine
phosphorylation of MAP kinase (Erk1/Erk2), one of the major
components in the Ras-MAP kinase signaling pathway. These
results suggest that actinomycin D could be a non-phosphoryl-
ated natural and cellular membrane-permeable SH2 domain
antagonist.
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1. Introduction
Activation of Ras is an important convergence point in the
mitogenic signaling pathway of receptor tyrosine kinases [1].
The most important components of the Ras signaling path-
way are Shc, Grb2, and Sos [2^4]. The Shc proteins contain-
ing the src homology 2 (SH2) domain are cytoplasmic sub-
strates of activated tyrosine kinases [5]. Shc is phosphorylated
in response to a variety of receptor tyrosine kinases [6] and
also by cytoplasmic tyrosine kinases such as Lck, Src, Fps or
Sea [7].
Shc contains a SH2 domain that binds to either receptor
tyrosine kinases upon ligand activation [5] or the phosphotyr-
osine-containing sequence [8]. Phosphorylated Shc then acts
as a linker or adapter for other SH2 domain-containing pro-
teins. One such protein is a 23^25 kDa Grb2 composed of two
SH3 domains and one SH2 domain [9]. The SH2 domain
binds to speci¢c phosphotyrosine motifs on receptors or other
adapter proteins such as Shc, whereas the SH3 domains asso-
ciate with proline-rich motifs in the C-terminal part of SOS, a
guanine nucleotide exchange factor for Ras proteins. Recruit-
ment of the Grb2-SOS complexes results in relocalization of
SOS to the membrane, in which the event is considered su⁄-
cient to induce Ras activation, then the activated Ras in turn
leads to Raf and mitogen-activated protein (MAP) kinase
activation [10].
Overexpression of the epidermal growth factor receptor
(EGFR) and erbB-2 has been found in a number of human
cancers [11]. The HER-2/neu (also known as erbB-2) proto-
oncogene encodes a 185 kDa transmembrane glycoprotein
(p185) with intrinsic tyrosine kinase activity homologous to
the EGFR [12]. Unlike EGFR and other receptor tyrosine
kinases, the mutated p185 tyrosine kinase is constitutively
active in the absence of exogenously added ligands. The tyr-
osine phosphorylation of Shc and formation of the Shc/Grb2
complex occur in neu* protooncogene-transformed NIH3T3
cells (B104-1-1) that express the mutation-activated p185
and in human breast cancer cells that overexpress p185 [13].
Interestingly, the transformed phenotypes of B104-1-1 are
largely reversed to the normal phenotype by the amino-termi-
nal SH3 deletion mutant of Grb2. These observations indicate
that the Shc/Grb2/SOS pathway plays an important role in
the oncogenic signaling pathway of the mutation-activated
p185 tyrosine kinase [6]. Moreover, recent studies have indi-
cated that communication from the EGFR to the mitogen-
activated protein kinase can be inhibited by blocking protein-
protein interaction at the Grb2 SH2 domain binding [14].
In an experiment of in vitro binding inhibitors screening for
Shc/Grb2 interaction, we discovered actinomycin C2, VII and
D as inhibitors from microbial origins [15,16]. Actinomycins
anchor into a purine-pyrimidine (DNA) base pair by interca-
lation, and then inhibit the mRNA synthesis. For this reason,
actinomycins have become a powerful tool for the study of
molecular and cell biology. In a recent study, it was reported
that cellular di¡erentiation was induced in actinomycin D-
treated rhabdomyosarcoma cells, whereas cell proliferation
was inhibited [17]. However, the mechanism of inhibition is
not well de¢ned. In this report, we describe that actinomycin
D inhibits Shc/Grb2 interaction in SAA and B104-1-1 cells
with a large number of Shc/Grb2 complexes in the presence
or absence of external stimulus, respectively. The association
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of Shc/Grb2 in B104-1-1 is constitutively formed without an
extracellular growth signal, but in SAA cells it is inducible
with EGF. We also elucidate that this inhibition of Shc/
Grb2 interaction by actinomycin D results in a decrease of
Erk1/Erk2 tyrosine phosphorylation in B104-1-1 cells.
2. Materials and methods
2.1. Antibodies
Peroxidase-conjugated secondary antibodies were obtained from
Transduction Laboratory (Lexington, KY, USA). Polyclonal anti-
body against Shc was from Upstate Biotechnology Inc. (Lake Placid,
NY, USA) and monoclonal antibodies against Grb2, Erk1, and phos-
photyrosine (PY20) were from Transduction Laboratory. Polyclonal
anti-phospho-Erk1 antibody was obtained from Promega (Madison,
WI, USA).
2.2. Molecular modeling of the Grb2(SH2)-actinomycin D complex
The peptide extracted from the Grb2(SH2) domain co-crystal struc-
ture was used as a template to build the bound conformation of
actinomycin D [18]. The three-dimensional conformation of actino-
mycin D was extracted from the X-ray crystal structure of the 2:1
complex between d(GAAGCTTC) and actinomycin D [19]. Calcula-
tions were performed on Silicon Graphics O2 computers running the
IRIX 5.x operating system. Energy minimizations were performed
with the Insight II/DISCOVER program (release 97.2, 1997, Bio-
sym/MSI) using the c¡91 force¢eld.
2.3. In vitro binding assay by ELISA
A 50 Wl aliquot of actinomycin D (20 Wg/ml) puri¢ed from Strepto-
myces sp. A1525 as previously described [15] was coated on polystyr-
ene 96 well plates (Falcon, Franklin Lakes, NJ, USA) for in vitro
binding assay by ELISA methods [20,24]. Non-speci¢c binding to
wells was inhibited by 5% bovine serum albumin (BSA) in TBS
(10 mM Tris, pH 7.5, 0.15 M NaCl). Recombinant GST-Grb2 (with
Grb2 whole protein) and GST-Grb2(SH2) (with the SH2 domain only
of Grb2) were obtained from Santa Cruz Biotech (Santa Cruz, CA,
USA). They were allowed to bind to the immobilized actinomycin D
at the indicated concentrations for 2 h. For the competition assay, 40
Wg/ml of Shc peptide (SpYVNVK, synthetic peptide with binding site
to Grb2 from Amersham, Piscataway, NJ, USA) [15] was added to
actinomycin D-coated wells with proteins. After extensive washing
with TBS containing 0.1% BSA, the binding of proteins was detected
using anti-GST antibody from Molecular Probes (Eugene, OR, USA)
and anti-rabbit IgG (Santa Cruz Biotech) conjugated with horseradish
peroxidase. Color reactions were performed with 3,3P,5,5P-tetra-
methylbenzidine (Boehringer Mannheim, Mannheim, Germany) as
substrate.
2.4. Cell lines and culture
SAA cells (NIH3T3 cells transfected with wild-type human EGFR)
were provided by Dr. Graham Carpenter (Vanderbilt University,
Nashville, TN, USA). SAA cells were grown to 95% con£uence in
Dulbecco’s modi¢ed Eagle’s medium (DMEM) containing 10% fetal
bovine serum (FBS), serum-starved for 18 h, and then treated with
actinomycin D in DMEM for 1 h [20]. Subsequently, cells were stimu-
lated with or without EGF (Boehringer Mannheim) for 15 min and
washed with cold phosphate bu¡ered saline (PBS).
B104-1-1 cells obtained from ATCC were plated into T185 £ask
(Nunc, Naperville, IL, USA) in DMEM supplemented with 10%
FBS and 50 WM 2-mercaptoethanol at 37‡C in a humidi¢ed 5%
CO2 atmosphere. After 24 h, cells were replenished with fresh com-
plete medium containing actinomycin D or 0.1% DMSO.
2.5. Preparation of non-denatured cell lysates
After EGF stimulation of SAA cells and in the case of B104-1-1
cells without any external stimulation, the cells were washed with
PBS, and then lysed in ice-cold lysis bu¡er (20 mM Tris-HCl, pH
7.5, 1% Triton X-100, 50 mM NaCl, 5 mM EGTA, 1 mM sodium
vanadate, 50 mM NaF, 30 mM Na4P2O7, 10% glycerol, 1 mM PMSF,
5 Wg/ml aprotinin, 10 Wg/ml leupeptin) for 1 h [21]. The cell lysates
were clari¢ed by centrifugation at 12 000 rpm for 20 min at 4‡C.
Protein concentrations of the cell lysate were determined against
BSA as standardized controls using the Bio-RadDC protein assay kit
(Bio-Rad, Hercules, CA, USA).
2.6. Immunoprecipitation and immunoblotting
Equivalent amounts of protein (500 Wg) of cell lysates were immu-
noprecipitated with anti-Shc antibody at 4‡C for 1 h [21]. After in-
cubation, pre-washed Pansorbin (Calbiochem, La Jolla, CA, USA)
was added for 1 h at 4‡C. The precipitation complexes were recovered
by centrifugation, washed three times with lysis bu¡er, and then
eluted with boiling in Laemmli SDS sample bu¡er. Samples were
subjected to electrophoresis under reducing conditions, and trans-
ferred to PVDF membranes (Millipore, Bedford, MA, USA). The
membranes were blocked with 0.1% gelatin in TTBS (10 mM Tris-
HCl, pH 7.6, 150 mM NaCl and 0.05% Tween 20), incubated with
primary antibodies for 1 h, washed three times, incubated with sec-
ondary antibodies for 1 h, and washed three more times. Speci¢c
antibody signals were detected with a chemiluminescence detection
kit (Amersham) [21].
2.7. Determination of MAP kinase tyrosine phosphorylation
B104-1-1 cells were plated at a density of 1U106 cells/10 cm dish
(Nunc) in DMEM supplemented with 10% FBS. One day after plat-
ing, the cells were starved of serum for 36 h, and either actinomycin D
(10, 25 or 50 nM) or 0.1% DMSO (control) was present during the
last 24 h [22]. Following removal of the medium, the cells were stimu-
lated for 8 h by the addition of fresh complete medium containing
Fig. 1. The structure of actinomycin D (A) and molecular modeling
of the Grb2(SH2)-actinomycin D complex (B). Actinomycin D con-
sists of two cyclopeptides (blue) and a chromophore moiety (red)
(A and B). The SH2 domain of Grb2 is in green (B).
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10% FBS in the absence or presence of actinomycin D. To determine
Erk tyrosine phosphorylation, cell lysates were resolved by SDS-
PAGE and then immunoblotting was performed with anti-phospho-
Erk or monoclonal anti-Erk antibody.
3. Results
3.1. A⁄nity of actinomycin D for Grb2
Molecular modeling studies were performed to see the bind-
ing mode of Grb2 and actinomycin D. Key elements for rec-
ognition are the phosphotyrosine and asparagine residues of
the phosphopeptide Lys-Pro-Phe-pTyr-Val-Asn-Val-NH2
whose side chains are seen to make multiple electrostatic
and hydrogen bond interactions with the protein in the
X-ray structure [18]. The SH2 domain-actinomycin D com-
plex was obtained by replacing the phosphotyrosine residue of
the X-ray structure with the chromophore moiety of actino-
mycin D and then minimized. Fig. 1B shows that within the
binding cavity, the complex has similar interactions between
the SH2 domain of Grb2 (green color) and the bound ligand
(blue color, peptide ring of actinomycin D).
To verify the Grb2 binding activity of actinomycin D, we
used the ELISA method. In the assay, an actinomycin
D-coated 96 well plate was incubated with recombinant pro-
teins, GST-Grb2 or GST-Grb2(SH2). Fig. 2 shows that Grb2
and Grb2(SH2) could bind to actinomycin D in a dose-de-
pendent pattern. In this assay, GST protein did not a¡ect
binding between Grb2/Grb2(SH2) and actinomycin D (data
not shown). This binding was also inhibited when Shc peptide
with binding site to Grb2(SH2) was added with proteins in a
reaction mixture.
3.2. Inhibition of Shc/Grb2 interaction in both SAA and
B104-1-1 cells
To learn the inhibitory activity of Shc/Grb2 interaction by
actinomycin D in cells, we used EGF-stimulated (SAA) cells
and endogenously activated (B104-1-1) cells due to expression
of activated growth factor receptor, erbB-2. To examine the
e¡ect of actinomycin D on EGF-induced Shc/Grb2 interac-
tion in cells, we delivered actinomycin D in SAA cells, and
then cells were stimulated by EGF. Co-immunoprecipitation
of Grb2 from cell lysates with anti-Shc antibody showed that
Grb2 proteins associated with the Shc protein when cells were
stimulated with EGF (Fig. 3A, lane 2). The inducible Shc/
Grb2 interaction was inhibited by treatment of actinomycin
D (10 nM, extracellular concentration) (Fig. 3). This result
indicates that actinomycin D inhibits Shc/Grb2 interaction
induced by EGF.
To learn the inhibitory e¡ect in B104-1-1 cells with endog-
enously activated Shc/Grb2 complex, we ¢rst examined the
e¡ects of incubation time from 1 to 48 h. After continuous
exposure to actinomycin D for 48 h, Shc/Grb2 interaction was
su⁄ciently inhibited in B104-1-1 cells (data not shown). Thus
cells were incubated with actinomycin D for 48 h in dose-
dependence experiments. To examine the concentration-de-
pendent inhibition of Shc/Grb2 interactions, we treated acti-
nomycin D at concentrations of 10, 25, or 50 nM for 48 h.
The protein complexes were immunoprecipitated from cell
lysates with anti-Shc antibody and the presence of Grb2 was
Fig. 2. In vitro binding assay of actinomycin D to Grb2 and
Grb2(SH2). An actinomycin D-coated polystyrene 96 well plate
(Falcon) was incubated with GST-Grb2 (A) or GST-Grb2(SH2) (B)
at the indicated concentration. For the competition assay, Shc pep-
tide was added to actinomycin D-coated wells with proteins. These
results were obtained from at least three independent experiments.
The means are shown with standard deviation.
Fig. 3. Inhibition of inducible Shc/Grb2 protein-protein interaction
in SAA cells. SAA cells (A) were grown as described in Section 2,
and then treated with indicated concentrations of actinomycin D in
DMEM for 1 h. Subsequently, cells were stimulated with or without
EGF for 15 min, washed with cold PBS, and lysed in lysis bu¡er.
The Shc/Grb2 complexes were immunoprecipitated with rabbit anti-
serum against Shc. The immunocomplexes were analyzed by immu-
noblotting using anti-Grb2 antibody (A). The blot used in A was
stripped and then probed with anti-phosphotyrosine (PY20) anti-
body (B) or with anti-Shc antibody to ensure equal loading of im-
munoprecipitated protein (C).
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assessed by immunoblotting with anti-Grb2 monoclonal anti-
body. We found that the formation of Shc/Grb2 complexes
was inhibited about 50% by treatment with 10 nM actino-
mycin D for 48 h (Fig. 4A). When the cells were treated
with 50 nM of the SH2 domain antagonist, the Shc/Grb2
complexes were almost completely dissociated. The results
demonstrated that actinomycin D inhibited Shc/Grb2 interac-
tion in a dose-dependent manner. The blots used in Fig. 4A
were stripped, re-blocked and re-probed with anti-Shc anti-
body to ensure equal loading of immunoprecipitated protein
(Fig. 4B).
3.3. Actinomycin D does not inhibit tyrosine phosphorylation of
Shc and expression levels of Shc/Grb2
We examined whether expression levels of Shc and Grb2
protein were a¡ected by actinomycin D, since actinomycin D
is a well-known DNA intercalating agent. We did not observe
any di¡erences between actinomycin D-treated cells and un-
treated ones in the expression levels of Shc and Grb2 up to 50
nM (Fig. 5B,C). At that concentration, actinomycin D com-
pletely blocked the formation of Shc/Grb2 complexes. Also,
actinomycin D did not inhibit tyrosine phosphorylation of
Shc, as shown in Fig. 5A. Therefore, these results show that
the number of Shc/Grb2 complexes in B104-1-1 was decreased
by the inhibition of actinomycin D of the protein-protein
interaction itself.
3.4. Inhibition of MAP kinase activity in actinomycin
D-treated cells
MAP kinases (Erk1/Erk2) are a member of the Ras signal-
ing pathway and play a crucial role in the transmission of
signals initiated at the plasma membrane by a variety of sig-
nals, including growth factors, oncogenes and di¡erentiating
agents. The inhibition of Erk1/Erk2 activity in actinomycin
D-treated cells was studied using monoclonal anti-Erk1 and
antiserum to phosphorylated Erk1, which can detect the tyr-
osine phosphorylation level of the Erk1/Erk2 proteins. As
shown in Fig. 6A, actinomycin D decreased the tyrosine phos-
phorylation of the Erk1/Erk2 in a dose-dependent manner
and the antagonist of Grb2-SH2 domain inhibited the phos-
phorylation of Erk1 and Erk2 with an IC50 of 50 and 40 nM,
respectively. However, the compound did not inhibit the ex-
pression levels of MAP kinases in lysates prepared from acti-
nomycin D-treated B104-1-1 cells (Fig. 6B).
4. Discussion
In previous studies, phosphotyrosine (pTyr) peptidomimet-
ics and non-phosphorus-containing pTyr mimetics as SH2
domain antagonists were discovered or synthesized for block-
ing intracellular signaling pathways via the SH2 domain [23].
These compounds strongly bind to the SH2 domain and some
of them are stronger antagonists than natural ligands. How-
ever, the inhibition activity of these antagonists, when applied
to intact cells, is limited because of their highly charged moi-
eties in physiological conditions [24,25]. In a recent report, a
non-phosphorylated cyclic peptide, which strongly binds the
SH2 domain of Grb2, does not show any inhibition activity in
cells, probably because the compound is also not permeable to
intact cellular membranes [26].
In contrast, actinomycin D could alleviate the limitations
because of its membrane permeability. Actinomycins are
DNA intercalating chemotherapeutic agents in the treatment
of various tumors. They also prevents the estrogen-induced
changes in glycolysis in human breast cancer cells [27]. Even
Fig. 4. Immunoprecipitation of Shc/Grb2 complexes in B104-1-1
cells. B104-1-1 cells were maintained in growth medium with in-
creasing concentrations of actinomycin D for 48 h. Cells were lysed
in lysis bu¡er, and then the Shc/Grb2 complexes were immunopre-
cipitated with rabbit antiserum against Shc. The immunoprecipitates
were analyzed by SDS-PAGE and immunoblotted using anti-Grb2
antibody (A). The blot used in A was stripped and then probed
with anti-Shc (B).
Fig. 5. E¡ects of actinomycin D on tyrosine phosphorylation of Shc
and protein expression levels of Shc and Grb2. B104-1-1 cells were
maintained in growth medium with increasing concentrations of ac-
tinomycin D for 48 h. Total cell lysates were separated by SDS-
PAGE and analyzed by immunoblotting with monoclonal anti-phos-
photyrosine PY20 (A), polyclonal anti-Shc (B) and monoclonal anti-
Grb2 antibody (C).
Fig. 6. Tyrosine phosphorylation of Erk1/Erk2 in B104-1-1 cells
treated with actinomycin D. Total cell lysates to examine tyrosine
phosphorylation of Erk1/Erk2 were prepared as described in Section
2. Cell lysates were resolved by SDS-PAGE and then immunoblot-
ting was performed with polyclonal anti-phospho-Erk1 (A) or
monoclonal anti-Erk1 antibody (B).
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though actinomycins have complex functions, the mechanism
of their biological functions, except a DNA intercalating func-
tion, is not well known yet. In our results, an interesting
aspect is that actinomycin D directly inhibits the protein-pro-
tein interaction via the SH2 domain at 10 nM, a much lower
concentration. Because the DNA binding constant of actino-
mycin D is around 2.3^3.3U107 M31, which is dependent on
the DNA sequences [28], the inhibition of transcription ex-
pression by actinomycin D is usually observed at a concen-
tration of 1^3 WM [29].
Human cancers develop as a result of the progressive accu-
mulation of genetic alterations in genes whose protein prod-
ucts play critical roles in cell proliferation [30]. Overexpression
of the EGFR and also erbB-2 has been found in a number of
human cancers, including bladder, colon, and lung cancers.
Previous studies on the EGFR signaling pathway indicated
that the Grb2/Sos complex could be recruited to tyrosine-
phosphorylated Shc or directly associated with the activated
EGF receptor. Xie et al. [6] reported that the Shc/Grb2/Sos
pathway was the most dominant one in coupling the activated
ErbB-2 to Ras since interference of the interaction between
Shc and Grb2 led to a dramatic inhibition of Ras activation
[13]. They suggested that the controlling agents of the Shc/
Grb2/Sos pathway might shed light on developing therapeutic
agents to block the oncogenic signaling pathway of the ErbB-
2 oncoprotein. Therefore our results suggest the possibility
that actinomycin D could be used as a chemotherapeutic
agent for EGFR- or ErbB-2-overexpressed tumors in addition
to ras-dependent tumors.
In conclusion, we report here that actinomycin D blocks
Shc/Grb2 interaction in EGFR-overexpressed NIH3T3
(SAA) and neu*-transformed NIH3T3 (B104-1-1) cells. There-
fore, this work provides a mechanistic explanation for growth
inhibition of cells with activated Ras signaling pathways, in-
cluding SAA and B104-1-1, by actinomycins and a new bio-
logical function of actinomycins. Our results also suggest that
actinomycin D will be a useful agent for the treatment of
speci¢c tumors caused by EGFR or the ErbB-2 oncogene.
In addition, such a structure will give an idea for the design
and development of new SH2 domain antagonists.
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